Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-057414
Filing Date
2023-11-01
Accepted
2023-11-01 16:01:39
Documents
87
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q srpt-20230930.htm   iXBRL 10-Q 4548064
2 EX-31.1 srpt-ex31_1.htm EX-31.1 13110
3 EX-31.2 srpt-ex31_2.htm EX-31.2 13180
4 EX-32.1 srpt-ex32_1.htm EX-32.1 9271
5 EX-32.2 srpt-ex32_2.htm EX-32.2 9119
  Complete submission text file 0000950170-23-057414.txt   14193107

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT srpt-20230930_cal.xml EX-101.CAL 76389
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT srpt-20230930_lab.xml EX-101.LAB 534041
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT srpt-20230930_def.xml EX-101.DEF 265929
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT srpt-20230930.xsd EX-101.SCH 78780
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT srpt-20230930_pre.xml EX-101.PRE 419028
81 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20230930_htm.xml XML 2885162
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14895 | Film No.: 231368098
SIC: 2834 Pharmaceutical Preparations